NCT06534125View on ClinicalTrials.gov

Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women with Early-Stage Breast Cancer

NARecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

December 12, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Anatomic Stage I Breast Cancer AJCC V8Anatomic Stage II Breast Cancer AJCC V8Anatomic Stage III Breast Cancer AJCC V8HER2-Negative Breast CarcinomaHormone Receptor-Positive Breast Carcinoma
Interventions
PROCEDURE

Acupressure Therapy

Undergo self-administered acupressure therapy to planned pressure points

DEVICE

Acupuncture Therapy

Undergo acupuncture therapy with acupuncture needles applied to planned pressure points

DRUG

Aromatase Inhibition Therapy

Receive SOC AI therapy

OTHER

Discussion

Ancillary studies

OTHER

Survey Administration

Ancillary studies

Trial Locations (4)

30303

RECRUITING

Grady Health System, Atlanta

30308

RECRUITING

Emory University Hospital Midtown, Atlanta

30322

RECRUITING

Emory University Hospital/Winship Cancer Institute, Atlanta

30342

NOT_YET_RECRUITING

Emory Saint Joseph's Hospital, Atlanta

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Emory University

OTHER

NCT06534125 - Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women with Early-Stage Breast Cancer | Biotech Hunter | Biotech Hunter